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Introduction: In the United States more than 6 million persons have chronic venous insufficiency and more than 500,000
have venous ulcers. Patients in whom conservative therapies fail may improve after surgical treatment of superficial and
perforating venous disease, but the degree of this benefit is uncertain.
Purpose: We performed a systematic review of health outcomes in patients with severe chronic venous insufficiency treated
with surgical management that incorporated subfascial endoscopic perforator surgery (SEPS), to quantify the overall
rates of surgical outcomes.
Methods: Published studies in English reporting venous ulcer healing and recurrence outcomes after SEPS were obtained
from a MEDLINE search. Data regarding patient characteristics and surgical outcomes were abstracted from each study,
and the outcomes were combined by using a random effects model.
Results: Our search identified 20 studies, 1 randomized trial and 19 case series, involving 1140 treated limbs. CEAP
classification was secondary cause (ES) in 36%, deep venous involvement (AD)in 56%, and obstructive (PO) in 12%.
Overall, after surgical treatment including SEPS, with or without concomitant superficial venous ablation, ulcers in 88%
of limbs healed. Ulcers recurred in 13%, at mean time of 21 months. Risk factors for nonhealing and recurrence included
postoperative incompetent perforator veins, pathophysiologic obstruction, secondary cause, and ulcer diameter greater
than 2 cm. Complications and their overall rates after surgical treatment including SEPS were wound infection (6%),
hematoma (9%), neuralgia (7%), and deep venous thrombosis (1%).
Conclusion: Our results suggest that surgical management of venous ulcer including SEPS, with or without saphenous
ablation, leads to an 88% chance of ulcer healing and a 13% chance of ulcer recurrence over the short term. Randomized
controlled trials are needed to discern the contributions of compression therapy, superficial venous surgery, and SEPS in
the treatment of venous ulcer disease. (J Vasc Surg 2004;39:583-9.)
More than 6 million persons in the United States have
chronic venous insufficiency,1 leading to treatment costs of
up to $2.5 billion2 and 2 million lost workdays annually.3
Venous ulcer accounts for much of this morbidity and
treatment cost, because the natural history of this disorder
is slow healing and high recurrence rate.4 Despite vigorous
efforts at conservative therapies such as compression dress-
ings and elevation, many patients fail to improve. Surgical
approaches such as the Linton procedure and subsequent
modifications of this procedure sought to eliminate perfo-
rator vein incompetence and therefore favorably affect ve-
nous hemodynamics and clinical outcome.5 While some
studies have reported good results, morbidity related to
wound complications has led many to abandon this proce-
dure.6
Subfascial endoscopic perforator surgery (SEPS) en-
ables surgeons to address perforator vein incompetence less
invasively, with small upper calf incisions remote from
severely diseased skin in the distal leg. SEPS is performed in
many centers as a component of a comprehensive treatment
program for venous insufficiency,7 but few studies have
compared SEPS with the Linton procedure. In the only
randomized trial, Pierik et al8 found similar ulcer healing
and recurrence rates and lower surgical complication rates
with SEPS, but the study was too small to enable definitive
conclusions about the efficacy of SEPS. The rest of the
studies incorporating SEPS have had an observational study
design, often without comparison treatment groups, so the
usefulness of SEPS in patients with venous disease remains
uncertain.
When there is controversy regarding the efficacy of an
intervention a systematic review of the literature to summa-
rize the available data may be helpful. In a systematic
review, investigators follow a specified protocol to conduct
a comprehensive literature search, to apply well-defined
inclusion and exclusion criteria to selected studies that
address the research question, and to critically appraise the
methodologic quality and applicability of the studies. When
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sufficient data exist, meta-analysis can be performed to
combine the data, with appropriate statistical methods to
increase the precision of the overall estimate of the treat-
ment effect.9 The goal of this systematic review is to sum-
marize the best available evidence on the outcomes of SEPS
for treatment of venous disease and to identify risk factors
for adverse outcomes associated with this procedure.
METHODS
The steps in performing a systematic review include
formulating a question, literature search and study retrieval,
critical appraisal and paper selection, data abstraction, and
statistical analysis and interpretation. We sought to answer
the question, What are the rates of various surgical out-
comes after SEPS for venous ulcer as reported in the
literature?
Literature search and study retrieval. We performed
a MEDLINE search in Ovid (Ovid Technologies, New
York, NY), using the MeSH terms “venous insufficiency/
surgery, varicose ulcer/surgery, and leg ulcer/surgery” or
the key word “perforator,” and combined these with the
exploded MeSH term “endoscopy,” and limited our search
to Human and English language studies. In addition we
searched references of review articles and of retrieved stud-
ies, and consulted local experts regarding recently pub-
lished papers. The initial search from 1966 to November
2002 provided 72 citations, and after two new trials were
reported in December 2002, the same search strategy in
January 2003 retrieved six additional citations.
Critical appraisal and paper selection. To be in-
cluded, a study must have reported the number of patients
with active ulceration at the time of SEPS and with ulcer
healing during follow-up. Because there was only one
randomized trial, we included nonrandomized studies in
our systematic review. We excluded studies with fewer than
10 patients with active ulcers. To minimize the risk for
double counting in the analysis of healing and recurrence,
we included only one paper when there were multiple
reports from the same institution during the same period.
When reported healing and recurrence outcomes could not
be clearly defined we contacted study authors.
Data abstraction. Two independent reviewers ab-
stracted the following data from the studies, using specified
data abstraction sheets: patient demographics; CEAP clas-
sification; outcomes, including healing, recurrence, and
complications; and factors associated with adverse out-
comes. We defined overall healing as the number of pa-
tients with class 6 disease that healed by the time of the
latest reported follow-up, but we also collected data on
healing within 30 days, within 60 days, and beyond 60 days
in the subset of studies reporting these data. Ulcer recur-
rence was recorded for patients with class 5 and class 6
disease that healed after SEPS. Complications included in
the analysis were infection, saphenous or sural neuralgia,
hematoma, and deep venous thrombosis (DVT). We also
collected data on risk factors associated with nonhealing
and ulcer recurrence.
Data analysis. We used a random effects model to
combine two kinds of data: proportions, such as percent of
limbs with ulcer healing; and odds ratios, which measure
the strength of the association between a risk factor, such as
secondary cause, and an outcome, such as failure to heal.
The random effects model incorporates both within-study
variance and between-studies variance in assigning a weight
to individual studies in a meta-analysis. Compared with the
fixed effects model, in which only within-study variance is
used for weight, the random effects model is generally more
conservative, usually resulting in a wider confidence
interval.
For combining proportions we used an extension of the
DerSimonian and Laird random effects model.10,11 We
calculated the logit of the proportion, then combined the
logits with a random effects model, and finally re-trans-
formed the result to arrive at a summary estimate.12 The
logit transform of the proportion was undertaken to ensure
that the data would comply with the normality assumption
for meta-analysis and that the resultant confidence intervals
would not be nonsensical (ie, confidence intervals with
values less than 0% or greater than 100%). Meta-analyses
were performed with Meta-analyst 0.99 computer software
(created by J.L.) to calculate point estimates and 95%
confidence intervals (CI).
RESULTS
Literature search. The literature search in January
2003 yielded 112 citations. This number was reduced to 78
after limiting to Human and English language studies.
After excluding duplicate reports, 18 articles had data on
healing outcomes after SEPS.6-8,13-27 Two studies found in
references of included studies were added,28,29 for a total of
20 included studies. Of these, 19 were case series and 1 was
a randomized trial that compared open perforator ligation
with SEPS.8
Patient characteristics. Study and patient characteris-
tics are listed in Table I. The studies included 1031 pa-
tients, with 1140 treated limbs. All patients had symptom-
atic venous insufficiency of clinical class I to III by previous
classifications, and class 2 to 6 by CEAP classification: 526
limbs (46%) had active ulcer at the time of SEPS, and 70%
of limbs with available data had CEAP class 5 or 6 disease.
Average age was 57 years (range, 44-67 years) in individual
studies, and 51% of patients were female (range, 11%-75%).
In the 4 studies that reported mean ulcer size, average
diameter was 6 cm (range, 2.8-9 cm).8,15,27,29 The average
duration of ulcer was 29 months (range, 8-144 months) in
the seven studies in which it was reported.6,8,15,17,24,27,29
Other CEAP characteristics indicating more severe ve-
nous disease included secondary cause (Es) in 36%, deep
venous insufficiency (AD) in 56%, and pathophysiologic
findings including obstruction (PO) in 12%. Because perfo-
rator vessel incompetence is de facto reflux, all limbs were
also designated as such (PR). Overall, 67% of patients
underwent concomitant procedures for superficial venous
insufficiency, including saphenous vein stripping and liga-
tion (Table I).
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Ulcer healing. The ulcer healing rate of the SEPS
arms of the 20 studies ranged from 56% to 100%. Combin-
ing all 20 studies, we found that ulcers healed in 88% (CI,
83%-92%) of limbs. The mean follow-up at which 17 of
these studies reported percentage of healing was 10
months. In the subset of 9 studies that reported healing by
time of follow-up,7,15,17,19,20,24,26,30,31 40% (CI, 27%-
53%; range, 31%-91%) of ulcers healed within 30 days, 64%
(CI, 53%-74%; range, 48%-100%) healed within 60 days,
and 86% (CI, 77%-92%; range, 56%-100%) healed after 60
days (Fig 1). From this subset the median time to healing
was 30 to 60 days. For ulcers that did not heal in the first 30
days, 40% healed by 60 days; and for ulcers that had not
healed by 60 days, 61% healed by the end of study
follow-up.
Ulcer recurrence. Probability of ulcer recurrence is
shown in Fig 2. For patients with class 5 disease at surgery,
ulcers developed in 16% (CI, 10%-24%; range, 0%-33%)
during follow-up. For patients with class 6 disease at sur-
gery in whom ulcers subsequently healed, 16% (CI, 11%-
21%; range 0%-28%) had ulcer recurrence during follow-
up. When patients with class 5 and class 6 disease were
combined, that is, all patients at risk for recurrence, 13%
(CI, 9%-18%; range 0%-28%) had ulcer recurrence. For the
8 studies that reported time of follow-up when ulcers
recurred (21 of 77 recurrences),7,8,14,18,19,22,28,29 mean
time to recurrence was 21 months. Total mean follow-up
among 16 studies reporting these data was 29
months.6-8,13-15,18-20,22-28
Risk factors for nonhealing. To explore risk factors
for nonhealing, we first identified factors examined in indi-
vidual studies. For each study with available data we then
estimated the odds ratio to quantify the association of
individual factors with nonhealing. Finally, we pooled odds
Table II. Factors associated with nonhealing
Risk factor
Pooled odds ratio
No. of
limbs
Point
estimate 95% CI P
Postoperative incompetent perforators8,22,23,32 73 7.6 1.5-38 .013
Size of ulcer 2 cm7,18,23 127 6.4 1.7-23 .0054
Etiology: secondary7,19,22,23,30 169 4.3 1.7-11 .002
Pathophysiology: obstructive7,22,23 140 2.2 0.3-14 .42
Anatomy: deep insufficiency7,22,24,27 221 1.3 0.7-2.5 .44
Saphenous ablation plus SEPS7,20,24 103 0.8 0.2-2.7 .74
SEPS, Subfascial endoscopic perforator surgery; CI, confidence interval.
Table I. Study characteristics
Study Year
No. of
patients
Age
(y)
Female
(%)
Limbs
treated
Disease
class
Limbs
with ulcer
Secondary
cause (%)
Anatomy
deep (%)
Pathophysiologic
obstruction (%)
Concomitant
saphenous
ablation (%)
Jugenheimer and
Junginger13
1992 72 23-81 71 103 I-III 17 NA NA NA NA
Pierik et al28 1995 38 56.3 74 40 NA 16 34 82 NA 11
Wolters et al29 1996 27 58 67 27 III 27 NA NA NA 0
Kulbaski et al14 1997 19 44 11 20 NA 17 NA NA NA NA
Pierik et al8 1997 20 64 55 20 6 20 NA 55 NA 70
Sparks et al15 1997 17 58 47 19 4-6 11 0 63 0 63
Lacroix et al16 1998 72 52 69 76 NA 18 12 24 4 88
Proebstle et al17 1998 32 57 75 40 I-III 16 38 NA NA 58
Rhodes et al18 1998 49 50 67 57 3-6 22 28 82 12 72
Illig et al19 1999 28 56.7 37 30 4-6 19 13 47 0 97
Murray et al20 1999 62 24-85 44 67 4-6 38 32 NA NA 53
Hauer et al21 1999 20 NA NA 22 II-III 17 NA NA NA NA
Gloviczki et al23 1999 146 56 46 146 2-6 101 38 72 6 60
Kolvenbach et al22 1999 19 66.7 37 19 5,6 10 42 42 26 89
Sato et al6 1999 25 60 36 27 4-6 20 37 67 22 70
Nelzen24 2000 138 58 59 149 3-6 36 NA 7 NA 89
Baron et al25 2001 41 60 22 45 4-6 37 NA NA NA 40
Lee et al26 2001 31 62 35 36 4-6 19 NA NA 0 92
Iafrati et al7 2002 45 58 38 51 5-6 29 51 76 6 69
Ciostek et al27 2002 130 28-72 61 146 3-6 36 65 33 15 90
Total 1031 1140 526
Overall average 57 51% 36% 57% 15% 63%
NA, Data not available.
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ratios to obtain a summary estimate of the association of
each risk factor with nonhealing (Table II).
The presence of postoperative incompetent perforator
vessels detected with Doppler ultrasound scanning was
reported to be a significant risk factor for nonhealing in two
studies8,32 of the four studies that reporting healing strati-
fied with this risk factor.8,22,23,32 Combining odds ratios
for these four studies resulted in significantly increased
odds for nonhealing in patients with postoperative incom-
petent perforator vessels. Ulcer diameter greater than 2 cm
was reported to be significantly associated with nonhealing
in three studies7,18,23 of the four studies that reported this
outcome.7,18,23,29 Data for odds ratios were available only
for the three positive studies, and combining these studies
resulted in a statistically significant increase in the odds of
nonhealing for ulcers greater than 2 cm in diameter. Six
studies reported healing stratified by primary versus sec-
ondary cause,6,7,18,19,22,23 and in two of these, secondary
cause was reported to be a significant risk factor for non-
healing.7,19 We calculated odds ratios in five studies (two
positive,7,19 three negative22,23,30), and combining these
showed a significant increase in odds of nonhealing in
patients with secondary cause. Note that confidence inter-
vals were wide, reflecting variation among studies (Table
II).
Results for patients with and without obstructive
pathophysiology were reported in four trials,7,18,22,23 one
of which found that obstruction was a significant risk factor
for nonhealing,23 and another found significantly longer
time to healing in patients with obstruction.18 Combining
the three trials with available data (one positive,23 two
negative7,22) did not find obstruction to be a significant risk
factor for nonhealing. Deep venous involvement was not a
significant risk factor for nonhealing in any of the five
studies that reported this outcome7,22-24,27 or in four stud-
ies combined that had available data.7,22,24,27 Four studies
reported healing results on the basis of concomitant saphe-
nous vein ablation.7,20,23,24 Combining the three studies
with available data7,20,24 resulted in a lower risk for non-
healing in patients who underwent concomitant saphenous
vein ablation, but this did not reach statistical significance
(Table II).
Two studies reported that the presence of a recurrent
ulcer at surgery, as opposed to a new ulcer, was not a
significant risk factor for nonhealing.18,23 Although two
studies reported that time to healing was longer in patients
with longer duration of ulcer before surgery,17,33 six stud-
ies found no association between duration of ulcer before
surgery and failure to heal.17,18,22,23,29,33 The two studies
with available data for odds ratios were not pooled, because
cutoff for duration in one study was 3 months31 and in the
other it was 35 years.22
Risk factors for ulcer recurrence. Factors associated
with recurrence are shown in Table III. Obstruction was a
significant risk factor for recurrence in two18,23 of three
studies.18,22,23 Combining odds ratios for these three stud-
ies resulted in a significant increase in odds of recurrence in
patients with obstruction. Secondary etiology was reported
to be a significant risk factor for recurrence in three18,20,23
of five studies that reported this outcome.7,18,20,22,23
Combining odds ratios for the four studies with available
data (two positive,18,20 two negative7,22) resulted in a
significant increase in odds of recurrence in patients with
secondary etiology. Again, CI were wide, reflecting varia-
tion among studies (Table III).
Postoperative incompetent perforator veins were a sig-
nificant risk factor for recurrence in two18,34 of the four
Fig 1. Cumulative ulcer healing. Box-and-whiskers plot depicts
ulcer healing after subfascial endoscopic perforator surgery in
patients with class 6 disease in subset of studies with data for time
to healing (nine studies, 264 limbs). y-axis shows percentage of
limbs that healed during follow-up; x-axis depicts three healing
end points, number of limbs, and number of studies that contrib-
uted to each end point. Horizontal lines, End points; boxes, 95%
confidence intervals; error bars, range for individual studies that
contributed to each estimate; Longest follow-up, healing by end of
follow-up.
Fig 2. Ulcer recurrence. Box-and-whiskers plot depicts ulcer re-
currence after subfascial endoscopic perforator surgery (SEPS).
y-axis shows percentage of limbs with ulcer recurrence during
follow-up; x-axis depicts three categories of limbs, number of
limbs, and number of studies that contributed to each end point.
Horizontal lines, Point estimates; boxes, 95% confidence intervals;
error bars, ranges for individual studies that contributed to each
estimate; class 5, recurrence in limbs with class 5 disease at SEPS;
class 6, recurrence in limbs with class 6 disease at SEPS in which
ulcers subsequently healed; combined, recurrence in limbs with
class 5 and class 6 disease. Number of limbs and studies in class 5
and class 6 do not total those in the combined group, because not
all studies reported data separately for limbs with class 5 and class 6
disease.
JOURNAL OF VASCULAR SURGERY
March 2004586 TenBrook et al
studies that reported this outcome,18,22,23,34 and combin-
ing data from these four studies resulted in a significant
increase in the odds of recurrence in patients with postop-
erative incompetent perforator vessels. Deep venous in-
volvement was not a significant risk factor for recurrence in
the four studies that reported this outcome7,22,23,28 or
when data were combined for the three studies with avail-
able data7,22,28 (Table III).
Complications after SEPS. Early surgical complica-
tions, as defined in each study, are shown in Fig 3. Wound
infection was reported in 6% of patients (CI, 4%-8%; range,
0%-16%). Hematoma was reported in 9% of patients (CI,
6%-13%; range, 0%-23%), but definitions of this end point
varied among studies. Some included mild hematomas;
others reported only those requiring repeat intervention.
Neuralgia was reported in 7% of patients (CI, 6%-9%; range,
0%-17%). Most studies did not specify whether the neural-
gia was persistent or transient, but one study reported a
much lower incidence of persistent neuralgia.27 DVT
within 30 days of operation was reported in 1% of patients
(CI, 0.7%-3%; range, 0%-2%). We included in this analysis
the seven studies that explicitly reported no DVT, but we
excluded several studies that reported no major complica-
tions without explicitly referring to DVT. No perioperative
deaths or pulmonary emboli were reported in these studies.
DISCUSSION
For patients with severe chronic venous insufficiency
and active venous ulcer, an intervention that improves
healing and recurrence has the potential to improve quality
of life and reverse disability associated with this condition.3
In our systematic review of mostly observational studies
with 1140 treated limbs in a patient population with severe
venous disease, surgical treatment that included SEPS, with
or without saphenous vein ablation, and conservative man-
agement resulted in healing of ulcers in 88% of limbs. An
estimated 40% healed by 30 days, and 64% by 60 days.
Ulcer recurrence in 611 limbs at risk was 13%, with mean
time to recurrence of 21 months. Complications from these
surgical procedures included wound infection in 6%, hema-
toma in 9%, neuralgia in 7%, and DVT in 1%, but serious
complications such as thromboembolism and perioperative
mortality were surprisingly low.
The healing and recurrence outcomes compare favor-
ably with trials of conservative therapies,35 even though the
patient population in these surgical studies generally had
severe venous disease and previous conservative therapies
had failed. Except for the 1991 study by Maybery et al,36
most other reports of compression therapy have found
lower healing rates.35 In a randomized controlled trial of
several medical treatments combined with compression
therapy, ulcers in 14% to 31% of patients healed by 4
weeks,37 less than the 40% healing at 30 days in the present
systematic review. Ulcer recurrence in 611 limbs at risk was
13%, with mean time to recurrence of 21 months, which
also compares favorably with conservative therapy.38
Identifying risk factors that predict poor outcomes,
such as nonhealing and recurrence after surgical approaches
that incorporate SEPS, would be useful clinically. Studies
reported different results on the association of risk factors
with adverse outcomes (Tables II and III), and understand-
ing this discrepancy is important. We found that postoper-
ative incompetent perforator veins, obstructive pathophys-
iology, secondary etiology, and larger ulcer increased the
odds of these adverse outcomes by about 4-four to 14-fold.
However, there is considerable uncertainty in the estimate,
as evidenced by the wide confidence intervals.
Reported outcomes such as healing and recurrence
varied broadly, and this may reflect differences in patient-
specific or technique-specific factors. The patient popula-
tions differed in the proportion of patients with several key
risk factors for adverse outcomes. Some studies that had
high healing rates may have had patients with favorable risk
profiles. The use of concomitant superficial venous insuffi-
ciency procedures also varied among studies (Table I),
which is important because saphenous vein ligation by itself
may improve outcome in venous disease. We were unable
to evaluate the direct effect of saphenous vein ablation,
because individual studies generally did not report out-
comes stratified by the use of concomitant procedures. For
example, patients who have already undergone saphenous
vein ablation before SEPS may represent a subgroup at
higher risk that may have poorer outcomes.
Other surgical characteristics that may contribute to
the variability in outcomes include extent of perforator
vesssel ligation, individual surgeon experience, and use of
skin grafting. We found that postoperative incompetent
perforator vessels are associated with nonhealing and recur-
rence, but it is not known whether these veins were missed
at operation or arose de novo.34 Variation in surgical tech-
nique and individual surgeon experience may account, at
least in part, for variation in rates of postoperative incom-
Table III. Factors associated with ulcer recurrence
Recurrence risk factor
Pooled odds ratio
No. of
limbs
Point
estimate 95% CI P
Pathophysiology: obstructive18,22,23 166 13.5 1.2-156 .037
Etiology: secondary7,18,20,22 166 5.9 1.2-30 .031
Postoperative incompetent perforators18,22-34 98 5.3 1.2-24 .03
Anatomy: deep insufficiency7,22,28 100 2.7 0.42-17 .3
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petent perforator vessels. Also, use of skin grafts varied
among studies (some routinely applied skin grafts in all
patients with large ulcers25), and this could have contrib-
uted to variability in outcomes. In the one study that
reported healing according to presence or absence of skin
grafting the healing rate was higher in patients with skin
grafts, but the difference was not statistically significant.17
Lack of adherence with compression stockings postop-
eratively was not significantly associated with ulcer recur-
rence in the North American Subfascial Endoscopic Perfo-
rator Surgery Registry (NASEPS),23 but this is the only
study reporting an outcome stratified by level of patient
adherence. Another study reported good adherence in
patients who responded to therapy.29 Other observational
studies have reported up to 100% recurrence rate in patients
who are noncompliant with compression therapy,36 so
adherence is probably important, and variability in compli-
ance among studies could also account for some of the
variability in outcomes.
There are several limitations of this systematic review.
First, most meta-analyses of interventions involve combin-
ing randomized controlled trials to estimate the relative
efficacy of one intervention over another. For this system-
atic review, data from all but one of the trials came from
cohorts that lacked a comparison group, so the efficacy of
SEPS cannot be directly compared with another treatment.
Studies differed in clinical characteristics of their popula-
tions, in their definitions of outcomes (hematoma or major
hematoma only), and in reporting of outcomes (specific
presence or absence of DVT). Also, because some patients
underwent bilateral surgery, some outcomes may have
been affected by clustering of risk factors for both limbs.
The NASEPS Registry contributed the largest number of
patients, but its inclusion in this analysis introduces some
difficulties. While we excluded studies identified by the
authors as part of the Registry, some included studies may
have been part of it, and therefore some patients may have
been counted twice.
As with any systematic review, the results are limited by
the available data. Publication bias, in which studies with
positive results are more likely to be published than those
with negative results, may be more prevalent for case series
than for randomized controlled trials. For overall healing,
all 20 studies had usable data, and for recurrence there were
18 studies. The analysis of risk factors associated with
adverse outcomes was limited to three to seven studies that
reported outcomes stratified according to patient charac-
teristics. In addition, analyses were performed on the subset
of three to five studies with data available for calculating
odds ratio. It is possible that the exclusion of a study or
studies that reported an association but did not have usable
data for meta-analysis could bias the result, so results of the
analysis of risk factors should be interpreted with caution.
More detailed individual patient data would enable con-
struction of statistical models adjusting for factors that
influence patient outcomes, and construction of meta-
analysis survival curves.39
Inclusion of some of the studies in this systematic
review may have resulted in less favorable results than might
be found today. For example, some of the studies presented
preliminary data and outcomes that might have reflected a
learning curve for the procedure. In a 1996 study ulcers did
not completely heal in four of nine patients,40 but in the
1999 mid-term report of the NASEPS Registry the cumu-
lative ulcer healing rate was about 88% at 1 year.23
In this study we endeavored to clarify the outcomes of
surgical treatment including SEPS and to report on factors
that affect outcomes. The statistical methods used enabled
us to make use of the published data. However, the quality
of any analysis depends on the quality of the data. In the
future authors should be encouraged to adhere to the
reporting standards in venous disease,41 to both support
their conclusions and enable future meta-analyses. This
systematic review demonstrated excellent results in terms of
ulcer healing and prevention of ulcer recurrence when
SEPS was used as part of a treatment regimen for severe
chronic venous insufficiency. However, prospective ran-
domized trials are required to define the relative contribu-
tions of compression therapy, superficial venous surgery,
and SEPS in the management of severe venous disease.
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